Financial reports
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
28 Oct 22
10-Q
2022 Q1
Quarterly report
21 Oct 22
10-K
2021 FY
Annual report
5 Oct 22
NT 10-K
Notice of late annual filing
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
10-Q
2021 Q1
Quarterly report
14 May 21
10-K
2020 FY
Annual report
22 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
Current reports
8-K
Material Modifications to Rights of Security Holders
1 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Jan 23
8-K
Entry into a Material Definitive Agreement
15 Nov 22
8-K
Entry into a Material Definitive Agreement
4 Nov 22
8-K
Other Events
27 Oct 22
8-K
Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF
24 Oct 22
8-K
Entry into a Material Definitive Agreement
17 Oct 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Sep 22
8-K/A
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting firm
22 Sep 22
8-K
Entry into a Material Definitive Agreement
8 Sep 22
Registration and prospectus
25-NSE
Exchange delisting
3 Mar 23
8-A12G
Registration of securities
1 Feb 23
D
$764.50 k in equity / options, sold $577.00 k, 12 investors
4 Nov 22
424B5
Prospectus supplement for primary offering
23 Mar 22
424B5
Prospectus supplement for primary offering
22 Mar 22
424B5
Prospectus supplement for primary offering
7 Feb 22
424B5
Prospectus supplement for primary offering
10 Sep 21
425
Business combination disclosure
17 Jun 21
424B3
Prospectus supplement
10 Jun 21
Proxies
DEFR14A
Revised proxy
28 Feb 23
DEF 14A
Definitive proxy
27 Feb 23
PRE 14A
Preliminary proxy
15 Feb 23
DEF 14A
Definitive proxy
28 Nov 22
PRE 14A
Preliminary proxy
18 Nov 22
DEF 14A
Definitive proxy
12 Oct 21
DEFA14A
Additional proxy soliciting materials
6 Nov 20
DEF 14A
Definitive proxy
6 Nov 20
DEF 14A
Definitive proxy
15 Mar 19
DEFA14A
Additional proxy soliciting materials
15 Mar 19
Other
EFFECT
Notice of effectiveness
11 Jun 21
CORRESP
Correspondence with SEC
8 Jun 21
CORRESP
Correspondence with SEC
4 Jun 21
UPLOAD
Letter from SEC
24 May 21
CORRESP
Correspondence with SEC
7 May 21
UPLOAD
Letter from SEC
25 Feb 21
EFFECT
Notice of effectiveness
1 Jun 20
UPLOAD
Letter from SEC
28 May 20
CORRESP
Correspondence with SEC
27 May 20
CT ORDER
Confidential treatment order
17 Nov 17
Ownership